BioLineRx Ltd - Company Profile
Powered by 
All the data and insights you need on BioLineRx Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date BioLineRx Ltd Strategy Report
- Understand BioLineRx Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
BioLineRx Ltd (BioLineRx) is a clinical-stage drug development company that undertakes the development of drugs for unmet medical needs in a wide range of disease conditions. The company follows a business model based on acquiring molecules from biotechnological companies, researchers, and universities and then performing feasibility studies. It advances the molecules across pre-clinical and clinical stages. Later, the company partnered with pharmaceutical companies for advanced clinical development and out-licensing of the developed drugs for manufacture and commercialization. Its clinical-stage therapeutic candidates include BL-8040 and AGI-134.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
BioLineRx's research and development activities are targeted at the creation of acquired and in-licensed therapies for the management of various immunological disorders and cancers. The company uses its expertise in research to create novel solutions for the human health industry. Through ongoing in-licensing and the development of fresh, dependable pharmaceutical products that address unmet medical needs, the company has always sought for mid- and long-term sustainable growth. BioLineRx runs a major research facility in Israel that is about 380 square meters in size. As of March 21, 2023, the business had a patent estate of around 33 patent families, which together contain more than 129 issued patents, 10 allowed patent applications, and more than 80 pending patent applications pertaining to its therapeutic prospects. In FY2022, the company spent US$17.6 million on its R&D.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer